都市激情在线亚洲国产91_欧美日韩国产国语对白_av成人毛片在线免费观看_少妇爆乳无码专区网站_亚洲Aⅴ无码吞精久久AV_亚洲AV毛片一区无码日韩_国产成人精品1024视频网站_最新综艺节目国产精品喷浆_国产在线拍揄自揄视频网站_天天少妇被猛烈进入在线播放

3358288340
CN
CN EN
Breaking News! Kexing Biopharm Teams Up with ANTIV to Develop Oral Antiviral Drugs for COVID-19

Release date:2022 - 02 - 21

Oral COVID-19 Drugs - the Last Piece of the Puzzle

The COVID-19 pandemic, characterized by the high and quick variability of its causative virus (SARS-CoV-2), is still prevalent worldwide. Several variants of the virus have appeared and spread across the world in waves of new outbreaks, causing concern and attracting wide attention. Although vaccination can give a certain degree of protection, it cannot completely prevent the spread of the virus nor effectively treat infected people. This is where the R&D for therapeutic drugs against the disease becomes imperative. Fortunately, several oral anti-COVID-19 drugs have been granted Marketing Authorization or Emergency Use Authorization overseas, while progress has also been made in the field in China.


Kexing Biopharm Joins in the Development of Oral Antiviral Drugs for COVID-19

On February 20, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as Kexing Biopharm) announced that Shenzhen Kexing Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm, signed the “SHEN 26 Project Cooperation Agreement” (hereinafter referred to as "Cooperation Agreement) with Shenzhen ANTIV pharma Co., Ltd. (hereinafter referred to as "ANTIV") on February 18, 2022. Globally, ANTIV exclusively licenses the intellectual property rights of SHEN 26 obtained or held by it to Shenzhen Kexing, and transfers the subsequent research and development rights, as well as the commercialization rights, to Shenzhen Kexing.

The signing of this Cooperation Agreement marks the acceleration of the Company's layout in innovator drugs, allowing the Company diversified product reserves, enhanced core competitiveness and enriched antiviral pipelines. All these will not only continuously improve the pharmaceutical R&D, manufacturing and sales system, but also promote the sustainable, rapid and sound development of the Company's business.


About SHEN 26

SHEN26 is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor, which can achieve antiviral effects by inhibiting viral nucleic acid synthesis. The laboratory development has already been completed and preclinical pharmaceutical and process development are undergoing. Meanwhile, relevant patent applications have been submitted to China National Intellectual Property Administration.  The SHEN 26 Project has been included in the 2021 Guangdong Provincial Emergency Response Projects for the Prevention and Control of COVID-19 Infection and has become one of the key special projects of the Ministry of Science and Technology of the People’s Republic of China for Public Safety Risk Prevention and Control and Emergency Technology Equipment.


About Kexing BIOPHARM

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein therapeutics and microecological agents. We focus on pharmaceutical research in the therapeutic fields of antiviral, oncology, immunology, hematology, digestion and degenerative diseases.which will benefit patients all over the world and help us turn into a leader in high-quality biologicals.

In recent years, we have achieved continued and rapid growth in its business, becoming a leader in the recombinant protein therapeutics industry. Our core products, remained at the forefront of similar varieties in China, have been adopted by over 18,000 sales terminals, including over 6500 hospitals in the provinces, municipalities and regions across China, and accessed into and sold in over 30 countries, including Brazil, Philippinesand Indonesia.


About ANTIV

Shenzhen ANTIV pharma Co., Ltd. is a biopharmaceutical company focusing on the R&D and sales of antiviral drugs, mainly focusing its research on diseases caused by viruses including coronaviruses, human immunodeficiency virus (HIV) and liver viruses, such as COVID-19, AIDS and hepatitis B.

ANTIV has two core members: Prof. Zhang Xumu, the dean of SUSTech Medi-X Pingshan, with main research interests in pharmaceutical chemistry, antitumor and antiviral small-molecule drugs, and green synthesis of chiral drugs; Prof. Guo Deyin, a professor of Zhongshan School of Medicine of Sun Yat-sen University and the president of Virology Division of Chinese Society for Microbiology, with main research interests in the pathogenesis of coronavirus infections and the mechanism of immune responses thereof, viral-vector gene therapy and antiviral drug screening.


2022最新韩国理伦片在线观看 | 99久久99久久精品国产片 | 亚洲综合另类小说色区 | 色婷婷AV无码久久精品 | miaa213永濑唯在线观看 | 乱码久久久久J午夜精品久久久久久 | 国产欧美日韩国中文字幕在线 | 麻花豆传媒剧在线观看免费高清 | 四虎影视国产精品亚洲精品 | 在线涩涩免费观看国产精品 | 91精品国产人成网站 | 大乱东京道一本热大交乱人妻 | 91久久久无码国产精品免费不卡 | 欧美成a人片免费看久久 | 午夜性色一区二区三区不卡视频 | 色婷婷AV一区二区三区在线观看 | 奶大交一乱一乱一视一频 | 含羞草实验研所传媒网站进入 | 2020天堂在线亚洲精品专区 | 国产精品色拉拉免费看 | 一级做a爰片久久毛片免费陪 | 18厘米大黑粗硬大吉吧 | 在线中文新版最新版在线 | 欧美自拍嘿咻内射在线观看 | 欧美精品黄页在线观看视频 | 国产亚洲第一伦理第一区 | 久久精品国产亚洲A片高清不卡 | 白天躁晚上躁天天躁2022 | 亚洲无线码一区国产欧美国日产 | 91在线一区二区 | 国产末成年AV一区二区三区 | 亚洲中文字幕无码中文字 | 少妇裸体婬交视频免费看高清 | chinese国产乱在线观看 | 一本久道综合在线无码人妻 | 亚洲AV产在线精品亚洲第一站 | 免费女人18a级毛片视频 | 国产精品一区在线观看你懂的 | 加勒比AV一本大道香蕉大在线 | 探花口爆颜射乳交日韩 | 国产特黄特色的大片观看免费视频 |